Altimmune (NASDAQ:ALT) Hits New 1-Year Low – Should You Sell?

Altimmune, Inc. (NASDAQ:ALT) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $2.55 and last traded at $2.5750, with a volume of 2028174 shares traded. The stock had previously closed at $2.66.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ALT. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Monday, September 21st. Evercore reiterated an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Leerink Partners started coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price target on the stock. HC Wainwright restated a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Altimmune Stock Down 2.8%

The stock’s fifty day moving average price is $3.08 and its 200 day moving average price is $3.03. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. The stock has a market cap of $502.83 million, a P/E ratio of -3.30 and a beta of 0.06.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. As a group, research analysts forecast that Altimmune, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC purchased a new position in shares of Altimmune in the 2nd quarter worth about $98,000. WINTON GROUP Ltd purchased a new position in shares of Altimmune during the 2nd quarter valued at about $49,000. Squarepoint Ops LLC raised its holdings in shares of Altimmune by 1,016.5% during the 2nd quarter. Squarepoint Ops LLC now owns 202,380 shares of the company’s stock valued at $615,000 after buying an additional 184,254 shares in the last quarter. Corient Private Wealth LP lifted its position in Altimmune by 77.5% in the 2nd quarter. Corient Private Wealth LP now owns 54,226 shares of the company’s stock worth $165,000 after buying an additional 23,673 shares during the last quarter. Finally, Syon Capital LLC bought a new stake in Altimmune in the 2nd quarter worth approximately $52,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc (NASDAQ:ALT) is a clinical-stage biotechnology company developing peptide-based therapeutics for metabolic and liver diseases. The company’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).

Altimmune’s development programs are focused on addressing obesity, related metabolic conditions and chronic liver disease.